Dcf Advisers, LLC Bristol Myers Squibb CO Transaction History

Dcf Advisers, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $303,922 - $339,832	5,250 New	5,250 $304,000
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $2 Million - $2.4 Million	-32,500 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $473,360 - $554,480	-8,000 Reduced 19.75%	32,500 $1.92 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $30,955 - $33,710	500 Added 1.25%	40,500 $2.71 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $86,610 - $98,145	-1,500 Reduced 3.61%	40,000 $2.48 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $86,145 - $95,460	1,500 Added 3.75%	41,500 $2.5 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $1.04 Million - $1.22 Million	-19,000 Reduced 32.2%	40,000 $2.35 Million
Q1 2020 May 12, 2020	SELL	$46.4 - $67.43 $23,200 - $33,715	-500 Reduced 0.84%	59,000 $3.29 Million
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $2.93 Million - $3.82 Million	59,500 New	59,500 $3.82 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.